



PRECISION IN
REGENERATIVE
AESTHETICS

Hair Filler

Regenerative peptide hair filler

A CE-approved hair filler developed for hair regrowth and scalp reconstruction – a patented 7-peptide complex with sustained-release technology.



The clinical burden of hair loss

50%

of men are affected by
androgenetic alopecia by
age 50

American Hair Loss
Association

40%

of women experience
noticeable hair loss by age
40

Population estimate

147M

people worldwide affected
by alopecia areata

Global prevalence

80%

of patients report
significant psychological
impact on quality of life

Patient-reported

Primary causes of hair loss

MOST COMMON

Androgenetic alopecia (AGA)

DHT-mediated follicle miniaturization; the most common form in both sexes. BMP4 and DKK-1 are the key pathological molecules.

CYCLICAL

Telogen effluvium

Triggered by stress, nutritional deficiency, or hormonal shifts. Disrupts the balance of the hair growth cycle.

AUTOIMMUNE

Alopecia areata

Autoimmune attack on hair follicles; affects roughly 2% of the global population across all ethnicities.

PERMANENT

Scarring alopecias

Permanent follicle destruction from inflammation, with limited conventional treatment options.


The hair growth cycle

Four phases define the therapeutic window. Peptides extend anagen and delay regression.


Anagen Growth phase Duration 2–7 yrs Population 85–90% Active proliferation of matrix cells; follicle deeply embedded in the dermis. PRIMARY TARGET — EXTEND PHASE	Catagen Regression phase Duration 2–3 wks Population 1–3% Programmed regression; follicle shrinks and detaches from the dermal papilla. Peptides aim to delay entry.	Telogen Resting phase Duration 3–4 mo Population 10–15% Follicle remains dormant. Excess telogen proportion leads to effluvium and visible thinning.	Exogen Shedding phase Duration Days Population <1% Active shaft release. Normal 50–100 hairs/day; pathological shedding significantly exceeds this.
---	--	--	--

The hair growth cycle

Four phases define the therapeutic window. Peptides extend anagen and delay regression.



The signalling pathway of hair loss



5α-Reductase converts testosterone into dihydrotestosterone (DHT).

DHT binds androgen receptors on the hair follicle.

Receptor binding drives DKK-1 and BMP4, blocking the Wnt growth signal.

Follicles progressively miniaturize; over time they die and the scalp becomes visible.

Scientific Background & Mode of Action :

- **01 Hair growth stimulation**
Enhances the expression of **genes involved in hair follicle development and regeneration**, promoting healthier and more sustained hair growth.
- **02 Inhibition of Alopecia**
Helps prevent hair loss by **suppressing the expression of BMP4 and DKK-1**, two key proteins involved in the inhibition of hair follicle development and growth.
- **03 Anti-oxidant effect**
Helps prevent alopecia by **reducing reactive oxygen species (ROS)** generated by UV exposure and physiological stress, thereby protecting hair follicles from oxidative damage.
- **04 Stimulation of Angiogenesis**
Promotes the formation of new blood vessels, enhancing nutrient and oxygen delivery to the scalp, which supports the development of healthy hair follicles.

The formulation ensures the sustained release of active peptides for approximately two weeks, maximizing efficacy with fewer treatment sessions. Each peptide in the complex is designed to target specific pathways involved in hair growth



Introducing ELYARATM Hair Filler

ELYARA Hair Filler is a CE-approved hair filler developed specifically for hair regrowth and scalp reconstruction.

THE PRODUCT

Introducing Elyara Hair Filler

ELYARATM PRECISION IN
REGENERATIVE
AESTHETICS

Elyara Hair Filler is a CE-approved hair filler developed specifically for hair regrowth and scalp reconstruction.

A patented peptide complex combined with sustained-release technology for targeted, prolonged scalp action. Supports hair regeneration and the prevention of hair loss. Activates hair-growth pathways and suppresses key causes of alopecia at the molecular level.



THE PRODUCT

Composition

ELYARA® Hair Filler contains a complex of seven innovative hair growth peptides, including:

- Decapeptide-18 (CG-WINT)
- Oligopeptide-54 (CG-Nokkin)
- Decapeptide-10 (CG-Keramin2)
- Octapeptide-2 (Prohairin-64)
- Decapeptide-18 (CG-WINT)
- Oligopeptide-54 (CG-Nokkin)
- Decapeptide-10 (CG-Keramin2)
- Octapeptide-2 (Prohairin-64)

Technology Platform

- Double Encapsulation Technology
- Patented Biomimetic Peptides
- Soft Formulation for Improved Comfort
- Easy to Inject application
- Visible Efficacy within 8 weeks (typically after 4 sessions)

Patents for 7 Biomimetic Peptides: [Patents](#)

Product variants

ELYARATM HAIR FILLER:

1ml ×1 or 1ml ×2
prefilled syringe.




Advanced Double Encapsulation Technology

A hyaluronic-acid hair filler carrying 7 biomimetic patented peptides in a double-encapsulation matrix.

Hyaluronic-acid carrier provides the injectable filler base and scalp hydration.

Double encapsulation protects peptides and releases them gradually.

Sustained release maintains active peptide concentration at the follicle over time.



Sustained release technology

I N T R O D U C I N G


HAIR-7

— P E P T I D E M A T R I X —

7-Peptide Bio-Signal Hair Restoration System




7 Patented Biomimetic Peptides. One Integrated System.



Sustained peptide release in the scalp


Fluorescence imaging shows peptide presence maintained from day 1 through day 14 after injection.

DermaLab
SkinLab
Ultrasound



Mode of Action for ELYARA Hair Fillers (Peptides)

Fluorescence imaging shows peptide presence maintained from day 1 through day 14 after injection.



02

The seven-peptide complex

A synergistic, multi-pathway approach to hair restoration — built on seven patented biomimetic peptides.



The 7-patent peptide architecture

Each peptide targets a distinct mechanism; together they act across the full hair-restoration cascade.

01

CG-Rehairin

Decapeptide-28

Stimulates follicles and prolongs anagen via WNT/ β -catenin.

02

CG-Edrin

Oligopeptide-71

Drives regrowth via WNT activation through NF κ B signalling.

03

CG-Prohairin β 4

Octapeptide-2

Activates follicle stem cells; boosts growth and ECM production.

04

CG-Wint

Decapeptide-18

Activates WNT/ β -catenin and SHH for new follicle neogenesis.

05

CG-Nokkin

Oligopeptide-54

BMP4 receptor blocker; inhibits DKK-1; reduces hair loss.

06

CG-Seperin

Octapeptide-11

Collagen production; skin firming and structural improvement.

07

CG-Keramin-2

Decapeptide-10

Follicle support; wound healing; skin renewal and calming.

Multi-pathway synergy

Growth activation, loss inhibition, and structural support in one complex.

CG-Rehairin – Decapeptide-28

MOLECULAR PROFILE	
INCI name	Decapeptide-28
Amino acids	10 a.a.
Mol. weight	1,306.5 Da
Source	Chemical synthesis
Liposome	Double-layered
Dosage	10–25 ppm
Application	Anti-aging, hair growth

MECHANISM OF ACTION

Generates hair-placode signalling to initiate new hair growth.
Activates anagen and delays the catagen regression phase.
Phosphorylates LRP6 – the specific WNT pathway co-receptor.
Increases β -catenin expression in a time-dependent manner.
Upregulates EP2 and Lef-1 transcription factors for growth programs.

PROLIFERATION

Dose-dependent rise in HaCaT keratinocyte & NIH3T3 fibroblast proliferation (SRB, OD590nm).

SIGNALLING

LRP6 phosphorylation by Western blot at 30 min; β -catenin rises 30 min → 3 hr.

TRANSCRIPTOMICS

RT-PCR: EP2 and Lef-1 increase at 1–12 hr – key mediators of hair growth.

CG-Edrin – Oligopeptide-71


MOLECULAR PROFILE

INCI name	Oligopeptide-71
Amino acids	12 a.a.
Mol. weight	1,447.6 Da
Source	Chemical synthesis
Liposome	Double-layered
Dosage	10–25 ppm
Application	Anti-loss, growth, thickness

MECHANISM OF ACTION

Promotes growth through NFkB-mediated WNT pathway activation.
Induces MAPKinase activation: p-JNK/SAPK, p-P38, p-ERK.
Down-regulates Ikb, implying activation of the NFkB signal.
Reduces DHT-induced keratinocyte apoptosis (anti-AGA).

NFkB SIGNALLING CASCADE



CG-Prohairin β4 – Octapeptide-2


MOLECULAR PROFILE

INCI name	Octapeptide-2
Amino acids	8 a.a.
Mol. weight	1,017.2 Da
Source	Chemical synthesis
Liposome	Double-layered
Dosage	10–25 ppm
Application	Hair growth

MECHANISM OF ACTION

Increases growth and migration of follicular cells.
Activates stem cells of the hair follicle bulge region.
Promotes fibroblast and keratinocyte proliferation (dose-dependent).
Long-term thermal stability at 37°C (70-day incubation).

EXTRACELLULAR MATRIX REGULATION · ELISA, 1 MG/ML, NIH3T3 VS. CONTROL



CG-Wint & CG-Nokkin

04 · NEOGENESIS

CG-Wint

Decapeptide-18

Contains a partial β -catenin sequence that mimics β -catenin to activate new follicle formation.

Activates the SHH (Sonic Hedgehog) pathway for dermal-papilla signalling.

Converts epithelial follicle stem cells into hair keratinocytes.

Increases thickness and restores growth in miniaturized follicles.

Best combined with CG-Nokkin and CG-Keramin-2.

05 · BMP4 BLOCKADE

CG-Nokkin

Oligopeptide-54

BMP4 receptor blocker – prevents BMP4 from binding its receptor.

Inhibits DKK-1 synthesis, a key molecule in androgenetic alopecia.

Prevents follicle miniaturization in AGA.

Improves scalp microcirculation and revitalizes follicles.

Prevents pigment loss; promotes strong hair.

CG-Seperin & CG-Keramin-2

06 · STRUCTURAL SUPPORT

CG-Seperin

Octapeptide-11 · 1,414.5 Da · 8 a.a. · 10–25 ppm

Reduces fine lines and wrinkles through new skin-cell generation.

Enhances skin tone with vitality and energy.

Dose-dependent fibroblast proliferation (72 hr, serum-free).

Supports scalp collagen structure that anchors follicles.

07 · SKIN RENEWAL

CG-Keramin-2

Decapeptide-10 · 10 a.a. · 10–25 ppm

Supports follicle activity; strengthens the hair shaft from the base.

Boosts dermal cell generation; reduces fine lines and wrinkles.

Promotes fibroblast and keratinocyte proliferation.

Calming and soothing; supports wound healing and cell renewal.

Integrated signalling pathways

Three mechanisms, seven peptides – growth activation, loss inhibition, and structural reinforcement.

WNT / β -Catenin

PEPTIDES

CG-Rehairin · CG-Wint · CG-Edrin

MECHANISM

Activates LRP6 → β -catenin accumulation → Lef-1 / EP2 transcription → anagen activation and follicle neogenesis.

Extended anagen phase

New follicle formation

BMP / DHT Inhibition

PEPTIDES

CG-Nokkin · CG-Edrin

MECHANISM

Blocks BMP4 receptor binding → inhibits DKK-1 synthesis → reduces DHT-mediated apoptosis → prevents miniaturization in AGA.

Reduced hair loss

AGA protection

ECM / Structural

PEPTIDES

CG-Prohairin β 4 · CG-Seperin · CG-Keramin-2

MECHANISM

Activates follicle stem cells → upregulates collagen (+38%), fibronectin (+320%), elastin (+20%) → strengthens the dermal scaffold.

Stronger hair shaft

Skin & scalp renewal

Patient Selection & Safety Information

IDEAL CANDIDATES

- Male Pattern Baldness: Norwood-Hamilton classification **Stage 2 to 4A**
- Female Pattern Baldness: SAVIN scale **Type I-I to II-2**
- Individuals with **non-scarring alopecia** conditions
- Patients in the **early to moderate stages** of hair loss
- Those with **realistic expectations** regarding treatment outcomes

CONTRAINDICATIONS

- Scarring alopecia
- Known **hypersensitivity** to any component of the formulation
- Active scalp **infections or inflammatory** conditions
- Severe **autoimmune diseases**
- **Pregnancy** and **lactation**

POTENTIAL SIDE EFFECTS

- Temporary **redness** at injection sites
- Mild **swelling or bruising**
- Temporary scalp **sensitivity or tenderness**
- Rare **allergic reactions**

Treatment Protocol & Administration

01



STANDARD PROTOCOL

- **Duration:** 8 weeks
- **Sessions:** 4 treatments (1 session every 2 weeks)
- **Follow-Up:** Clinical assessment upon completion of the initial protocol
- **Maintenance:** Repeat sessions every 3 to 6 months, depending on the individual's response and treatment goals

02



INJECTION TECHNIQUE

- **Spacing:** Injection points placed every **0.2–0.3 cm**
- **Pattern:** Lines spaced approximately **1.0 cm** apart
- **Depth:** Superficial
- **Volume per Point:** **0.02–0.05 ml**
- **Total Volume per Session:** 1 ml or more, depending on the treatment area and individual needs

03



PREPARATION

Materials Required:

- ELYARA® Hair Filler (1 cc gel)
- 30G needle
- Topical anesthetic cream
- Alcohol swabs
- Sterile gloves
- **Camera** (for before-and-after documentation)

04



POST-TREATMENT CARE

- **Avoid touching or washing** the treated area for at least 4 hours
- Avoid **direct sunlight** exposure for **24–48 hours**
- Refrain from **vigorous exercise** for 24 hours
- **Apply Pelobaum Hair Revitalizing Solution** to the treated scalp area as recommended

Treatment Protocol & Administration

IN-VITRO STUDIES

- Demonstrated **significantly higher cell proliferation** compared to competitor formulations
- Enhanced **hair shaft elongation**, indicating accelerated follicular activity
- Achieved a **29% increase** in cell proliferation
- Stimulated **collagen type I expression**, supporting scalp structure and follicle anchoring
- Induced **38% stronger keratinocyte proliferation** versus competing products
- Protected cells from **UVB-induced apoptosis**, aiding scalp and follicle health
- Promoted **tube formation** in human endothelial cells, suggesting improved angiogenesis

IN-VIVO STUDIES

Demonstrated **significant hair growth stimulation** in mouse models, including:

- Induction of the **anagen phase** (active growth phase of the hair cycle)
- Increased **hair follicle size**
- Higher hair follicle **density** and **count**

HUMAN CLINICAL STUDIES

PROTOCOL

- Duration: 8 weeks
- 4 treatment sessions (1 session every 2 weeks)

RESULTS

Hair Density: Increased by **22.3%** after completing the treatment protocol

Hair Thickness: Improved by **26%** compared to baseline measurements

Patient Satisfaction: High levels of satisfaction were reported across various types of **non-scarring alopecia**

03

Clinical evidence & efficacy

In-vitro, in-vivo, ex-vivo, and human studies of the peptide complex against control and minoxidil.


Dermal matrix cell proliferation

Cell	Human hair dermal matrix cells
Culture time	72 hours
Method	SRB staining
Concentration	Complex 10 µg/ml • Minoxidil 1 µg/ml


RESULT

Density and proliferation of HHDMCs increased after 72 hr of incubation with the peptide complex, compared with minoxidil – matrix-cell proliferation drives hair elongation in the anagen phase.


Control



Peptide complex



Competitor




Collagen Type I expression

Cell	Human hair dermal matrix cells
Culture time	24 hours
Method	RT-PCR
Concentration	Complex 10 µg/ml · Minoxidil 1 µg/ml

RESULT


The peptide complex positively regulated collagen Type I expression versus control and competitor. Collagen maintains the structural strength of hair.



Human Hair Dermal Fibroblast Proliferation

Culture time: 72hrs Method: MTT assay

Optimal Concentration: Peptide complex 10ug/ml, Competitor(Minoxidil) 1ug/ml



The effect of peptide complex on human hair dermal fibroblast

The assay was performed 72hrs after treatment of peptide complex. Peptide complex increased human hair dermal fibroblast proliferation(129%) better than minoxidil(113%).

Human Hair Keratinocyte Proliferation

Culture time: 72hrs Method: MTT assay

Optimal Concentration: Peptide complex 10ug/ml, Competitor(Minoxidil) 1ug/ml


the rapid growth and multiplication of keratinocytes, the main cells in your skin's outer layer (epidermis)

RESULT

The effect of peptide complex on human Keratinocyte

The assay was performed 72hrs after treatment of peptide complex.

Peptide complex increased human hair




Hair keratin gene expression

Cell	Human hair keratinocytes
Culture time	24 hours
Method	RT-PCR
Markers	Ha3-II · Keratin-14

RESULT

The complex increased transcription of hair keratin genes Ha3-II and Keratin-14 — differentiation markers essential to forming the hair shaft (ORS, IRS).




Inhibition of UV-induced apoptosis

Cell	Hair follicle dermal papilla cells
Culture time	3 days
Method	SRB staining
Conditions	UVB 50 mJ · complex 10 µg/ml

RESULT

UVB irradiation caused significant dermal-papilla cell death; the peptide complex reversed this UVB-induced apoptosis. Dermal-papilla apoptosis initiates hair loss.




Anagen-related protein expression

Cell	Hair follicle dermal papilla cells
Culture time	24 hours
Method	Western blot
Markers	HGF · IGF-1 · VEGF

RESULT

Increased expression of anagen-related growth factors HGF, IGF-1, and VEGF. Dermal-papilla cells secrete these factors to initiate anagen and regulate the hair cycle.




Angiogenesis & tube formation

Cell	HUVECs
Culture time	24 hours
Method	Matrigel tube formation
Concentration	Complex 10 µg/ml


RESULT

Endothelial tube formation was observed after treatment with the peptide complex. Angiogenesis regulates hair growth and follicle size.


Control



Peptide complex



Competitor




Inhibition of DHT-induced gene expression

Cell	Hair follicle dermal papilla cells
Culture time	24 hours
Method	RT-PCR
Markers	DKK-1 · Androgen receptor

RESULT

Decreased DKK-1 gene expression with the peptide complex under DHT stimulation. DKK-1 is the key molecule of androgenetic alopecia.



IN VIVO & EX VIVO STUDY

Follicle organ cultures and animal models confirm the in-vitro findings

DKK-1 challenge, placode formation, WNT/ β -catenin expression, and direct hair-filler injection.

Inhibition of DKK-1-induced hair loss

Model	Hair follicle organ culture
Duration	10 days
Challenge	DKK-1 + starvation
Groups	Control · DKK-1 · complex · complex+DKK-1



RESULT

DKK-1 caused severe follicle degeneration. The peptide complex prevented degeneration even in the presence of DKK-1, producing healthier follicles and shafts.


Control



DKK-1





Peptide complex



Peptide complex +DKK-1

New hair placode formation



New hair placodes were detected in peptide complex treatment even in the existence of DKK-1 in hair tissue culture after 10 days.

DKK-1 treated group has shown many cysts (dead hair follicles) formation.

Hair Placode differentiated to hair follicle from the bottom of epidermis basal layer.

Keratin-17 expression

Marker	Keratin-17 (placode marker)
Model	Hair tissue culture
Duration	15 days
Challenge	± DKK-1

RESULT


Keratin-17 was detected in the basal layer of hair placodes under complex treatment even with DKK-1, while the DKK-1 group showed no Keratin-17 expression.




WNT & β -catenin expression

WNT expression


CONTROL




DKK-1



Peptide complex




Peptide complex +DKK-1




β -catenin expression


Control




DKK-1



Peptide complex



Peptide complex +DKK-1





WNT and β -catenin expression (brown color) was detected in the hair follicle with peptide complex treatment even in the existence of DKK-1 in hair tissue culture after 15days. DKK-1 treated group has shown degenerated hair follicle.

Human hair follicle organ culture

Tissue	Human hair follicle
Method	Serum-free organ culture
Peptides	CG-Keramin-2 · CG-Nokkin · CG-Wint (1 µg/ml each)
Timepoints	Before · 2 days · 8 days

RESULT

Hair shafts elongated after 72 hr of organ culture. The peptide complex showed a synergistic effect compared with single-ingredient treatment.



IN VIVO STUDY · O

Hair filler injection (in vivo)

ELYARATM
PRECISION IN
REGENERATIVE
AESTHETICS

Control (PBS)



FEB.28 Before 3rd injection (day 14)

**ELYARA
BioRegenerative
Hair Filler**




FEB.28 Before 3rd injection (day 14)


Hair Filler injection (Skin Histology (H&E Staining))

Control



X40



X100



Treatment (New Filler after 1 injection: (7 days))




04

Human clinical studies

Thirty-two cases across androgenetic alopecia, female pattern hair loss, and alopecia areata.

Summary of clinical outcomes



HAIR DENSITY

- ELYARA® Hair Filler significantly improved the hair density compared to baseline (D0).
- According to the results of this study, hair density was improved in this period by approximately **22.5%** compared to baseline.

HAIR THICKNESS

- ELYARA® Hair Filler significantly improved hair thickness compared to baseline (D0).

Improvement in
hair thickness

26%
increase

ELYARA Hair Filler was found active in the improvement of male pattern hair loss, female pattern hair loss and Alopecia Areata in this study after local treatment of 8weeks

Androgenetic alopecia

Gender Male

Age —

Protocol 6 sessions · 1 / 2 weeks

Before



After



Androgenetic alopecia

Gender Male

Age —

Protocol 6 sessions · 1 / 2 weeks

Before

After



Cancer patient

Gender Male

Age —

Protocol 4 sessions · 5-month follow-up

Before



After



Androgenetic alopecia

Gender Male

Age —

Protocol 4 sessions · 1 / 2 weeks

Before



After



Androgenetic alopecia

Gender Male

Age —

Protocol 4 sessions · 1 / 2 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 31

Protocol 4 sessions · 1 / 2 weeks

Before



After



Androgenetic alopecia

Gender Male

Age —

Protocol 4 sessions · 1 / 2 weeks

Before



After



Androgenetic alopecia

Gender Male

Age —

Protocol 6 sessions · 1 / 2 weeks

Before



After



Androgenetic alopecia

Gender Male

Age —

Protocol 8 sessions · 1 / 2 weeks

Before



After



Female hair loss

Gender Female

Age —

Protocol 5 sessions · 1 / 2 weeks

Before



After



Female hair loss

Gender Female

Age —

Protocol 5 sessions · 1 / 2 weeks

Before



After



Female hair loss

Gender Female

Age 31

Protocol 4 sessions · 1 / 2 weeks

Before



After



Female hair loss

Gender Female

Age —

Protocol 4 sessions · 1 / 2 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 40

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 28

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 41

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 41

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 46

Protocol 4 sessions · 2-month follow-up

Before



After



After



Androgenetic alopecia

Gender Male

Age 47

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 47

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 43

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 43

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 33

Protocol 4 sessions · 8 weeks

Before



After



HUMAN CLINICAL STUDY · CASE 24

Androgenetic alopecia

Gender Male

Age 38

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 45

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 53

Protocol 4 sessions · 8 weeks

Before



After



HUMAN CLINICAL STUDY · CASE 27

Androgenetic alopecia

Gender Male

Age 55

Protocol 4 sessions · 8 weeks

Before



After



Androgenetic alopecia

Gender Male

Age 50

Protocol 5 sessions · 10 weeks

Before



After



Female hair loss

Gender Female

Age 58

Protocol 4 sessions · 2-month follow-up

Before



After



Autoimmune disease

Gender Female

Age 40

Protocol Serial injections



Alopecia areata

Gender Female

Age 33

Protocol 2 sessions · 4 weeks

Before



After 2 weeks



After 4 weeks



Alopecia areata

Gender Female


Age 35

Protocol 4 sessions · 8 weeks

Before



After





Thank you

Precision in regenerative aesthetics — for hair regrowth and scalp reconstruction.